Ayesha Junaid, a final-year MBBS student at Dow Medical College, shared a post on LinkedIn:
Join us at MedNews Week x OncoDaily for an insightful discussion with Dr. Elad Sharon: Navigating the Intersection of Immunotherapy and Autoimmunity.
The rapid expansion of cancer immunotherapy has transformed oncology while introducing new challenges in the recognition and management of immune-related toxicities.
In this MedNews Week episode, Dr. Elad Sharon, Clinical and Translational Director of the Immunotherapy Toxicity Program at Dana-Farber Cancer Institute and Faculty Member at Harvard Medical School, provides an evidence-based discussion on:
- Immune checkpoint inhibitors and emerging immunotherapy strategies
- Mechanisms and management of immune-related adverse events
- Biomarker-driven approaches to precision oncology
- Clinical decision-making in special patient populations
- Future directions in translational immuno-oncology
The discussion also features an insightful Q and A addressing tuberculosis reactivation, autoimmune diseases, personalized cancer vaccines, public-private partnerships in oncology drug development, and career development for aspiring physician-scientists. This session offers valuable clinical and research perspectives.
Watch now on the MedNews Week YouTube channel
A special note of gratitude to our mentors Yan Leyfman, Chandler Park and to the entire MedNews Week team for the collective effort behind bringing meaningful scientific conversations Zara Baloch, Adeena Musheer, Diksha Sanjana Pasnoor, Maduri Balasubramanian, Soumiya Nadar, Hur Abbas, Jenna Ghazal, Muskan Joshi.
Read other articles about MedNews Week on OncoDaily.